- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07626411
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation (ROXI-EVEREST)
A Phase 3, Randomized, Multicenter, Double-blind Study to Assess Stroke and Systemic Embolism Prevention With REGN7508, a Monoclonal Antibody Against Factor XI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-EVEREST)
This study is researching an experimental drug called REGN7508 (called "study drug") and how it compares against another treatment called apixaban. The study is focused on people who have atrial fibrillation, which means that the heart beats too fast and unevenly.
The aim of the study is to see how safe and effective REGN7508 is in preventing stroke and/or systemic embolism in participants with atrial fibrillation and how it compares against participants that will receive apixaban in this study.
The study is looking at several other research questions, including:
- What side effects may happen from taking the study drug
- Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 3
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Clinical Trials Administrator
- Número de teléfono: 844-734-6643
- Correo electrónico: clinicaltrials@regeneron.com
Ubicaciones de estudio
-
-
-
Longueuil, Canadá, J4H4B9
- Reclutamiento
- Viacar Recherches Cliniques inc.
-
-
Ontario
-
Hamilton, Ontario, Canadá, L8L 5G4
- Reclutamiento
- Premiere Clinical Trial Network
-
-
Quebec
-
Sherbrooke, Quebec, Canadá, J1LOK3
- Reclutamiento
- Diex Recherche Inc.
-
-
-
-
Alabama
-
Alexander City, Alabama, Estados Unidos, 35010
- Reclutamiento
- Advanced Cardiovascular
-
Dothan, Alabama, Estados Unidos, 36305
- Reclutamiento
- SEC Clinical Research
-
Fairhope, Alabama, Estados Unidos, 36532
- Reclutamiento
- Eastern Shore Research Institute
-
-
Arizona
-
Glendale, Arizona, Estados Unidos, 85306
- Reclutamiento
- West Valley Clinical Trials
-
Scottsdale, Arizona, Estados Unidos, 85260
- Reclutamiento
- Scottsdale Clinical Trials
-
-
Arkansas
-
Little Rock, Arkansas, Estados Unidos, 72205
- Reclutamiento
- Arkansas Cardiology P.A.
-
-
California
-
Covina, California, Estados Unidos, 91723
- Reclutamiento
- Valley Clinical Trials, Inc
-
Fremont, California, Estados Unidos, 94538
- Reclutamiento
- Mission Cardiovascular Research Institute
-
Huntington Beach, California, Estados Unidos, 92648
- Reclutamiento
- National Institute of California Heart and Vein Specialists
-
Inglewood, California, Estados Unidos, 90301
- Reclutamiento
- Alliance Clinical Los Angeles
-
La Jolla, California, Estados Unidos, 92037
- Reclutamiento
- Profound Research LLC at San Diego Cardiovascular Associates
-
Newport Beach, California, Estados Unidos, 92663
- Reclutamiento
- Radin Cardiovascular Medical Group
-
Northridge, California, Estados Unidos, 91325
- Reclutamiento
- Valley Clinical Trials, LLC dba Flourish Research
-
Pasadena, California, Estados Unidos, 91105
- Reclutamiento
- Southern California Heart Specialists
-
Santa Maria, California, Estados Unidos, 93454
- Reclutamiento
- FOMAT - Comprehensive Cardiovascular Care
-
Ventura, California, Estados Unidos, 93003
- Reclutamiento
- Cardiology Associates Medical Group
-
West Hills, California, Estados Unidos, 91307
- Reclutamiento
- Interventional Cardiology Medical Group
-
-
Florida
-
Boca Raton, Florida, Estados Unidos, 33434
- Reclutamiento
- Excel Medical Clinical Trials, dba Flourish Research
-
Cutler Bay, Florida, Estados Unidos, 33189
- Reclutamiento
- Nouvelle Clinical Research LLC
-
Inverness, Florida, Estados Unidos, 34452
- Reclutamiento
- Nature Coast Clinical Research - Inverness
-
Medley, Florida, Estados Unidos, 33166
- Reclutamiento
- South Florida Research Organization LLC
-
New Smyrna Beach, Florida, Estados Unidos, 32168
- Reclutamiento
- Healix Clinical Research
-
Pensacola, Florida, Estados Unidos, 32503
- Reclutamiento
- Sec Clinical Research
-
Saint Augustine, Florida, Estados Unidos, 32086
- Reclutamiento
- Flourish Research, St. Johns Center for Clinical Research
-
Sarasota, Florida, Estados Unidos, 34239
- Reclutamiento
- Cardiovascular Center of Sarasota Foundation for Research and Education
-
Winter Park, Florida, Estados Unidos, 32789
- Reclutamiento
- Clinical Site Partners, LLC DBA Flourish Research
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30342
- Reclutamiento
- Atlanta Clinical Research Centers
-
Atlanta, Georgia, Estados Unidos, 30310
- Reclutamiento
- Morehouse School Of Medicine
-
Johns Creek, Georgia, Estados Unidos, 30024
- Reclutamiento
- NSC Research, Inc
-
-
Indiana
-
Hobart, Indiana, Estados Unidos, 46342
- Reclutamiento
- Profound Research, Advanced Cardiovascular Care + Electrophysiology Clinic
-
Munster, Indiana, Estados Unidos, 46321
- Reclutamiento
- Profound Research, Powers Health Medical Group - Electrophysiology
-
Munster, Indiana, Estados Unidos, 46321-4054
- Reclutamiento
- Cardiovascular Research of Northwest Indiana, LLC
-
-
Louisiana
-
West Monroe, Louisiana, Estados Unidos, 71291
- Reclutamiento
- Monroe Research, LLC
-
-
Maryland
-
Ft. Washington, Maryland, Estados Unidos, 20744
- Reclutamiento
- Anderson Medical Research
-
-
Massachusetts
-
Foxborough, Massachusetts, Estados Unidos, 02035
- Reclutamiento
- K2 Medical Research, Foxboro
-
-
Michigan
-
Bloomfield Hills, Michigan, Estados Unidos, 48304
- Reclutamiento
- Profound Research, Cardiology and Vascular Associates (CAVA) - Bloomfield Hills
-
Farmington Hills, Michigan, Estados Unidos, 48334
- Reclutamiento
- Profound Research, Millennium Cardiology
-
Flint, Michigan, Estados Unidos, 48503
- Reclutamiento
- Flint Clinical Research
-
-
New York
-
Staten Island, New York, Estados Unidos, 10309
- Reclutamiento
- Super Health Pharmacy
-
-
North Carolina
-
Concord, North Carolina, Estados Unidos, 28025
- Reclutamiento
- Hawthorne Health, Moose Pharmacy of Concord
-
High Point, North Carolina, Estados Unidos, 27260
- Reclutamiento
- Peters Medical Research
-
-
North Dakota
-
Fargo, North Dakota, Estados Unidos, 58104
- Reclutamiento
- Lillestol Research LLC
-
-
Ohio
-
Marion, Ohio, Estados Unidos, 43302
- Reclutamiento
- K&R Research LLC
-
Maumee, Ohio, Estados Unidos, 43537
- Reclutamiento
- Advanced Medical Research
-
-
South Dakota
-
Rapid City, South Dakota, Estados Unidos, 57701
- Reclutamiento
- Monument Health Clinical Research
-
-
Tennessee
-
Tullahoma, Tennessee, Estados Unidos, 37388
- Reclutamiento
- Tennessee Center for Clinical Trials
-
-
Texas
-
Amarillo, Texas, Estados Unidos, 79106
- Reclutamiento
- PharmaTex Research
-
Brownsville, Texas, Estados Unidos, 78520
- Reclutamiento
- PanAmerican Clinical Research
-
Houston, Texas, Estados Unidos, 77061
- Reclutamiento
- Synergy Groups Medical
-
Houston, Texas, Estados Unidos, 77094
- Reclutamiento
- West Houston Area Clinical Trial Consultants, LLC
-
Missouri City, Texas, Estados Unidos, 77459
- Reclutamiento
- Synergy Group Medical, LLC
-
Odessa, Texas, Estados Unidos, 79761
- Reclutamiento
- Permian Research Foundation
-
Tyler, Texas, Estados Unidos, 75701
- Reclutamiento
- Tyler Cardiovascular Consultants
-
-
Utah
-
Clinton, Utah, Estados Unidos, 84015
- Reclutamiento
- Alpine Research TC
-
-
Virginia
-
Manassas, Virginia, Estados Unidos, 20109
- Reclutamiento
- Carient Heart & Vascular
-
Vienna, Virginia, Estados Unidos, 22182
- Reclutamiento
- Conquest Research
-
-
-
-
Hokkaido
-
Sapporo, Hokkaido, Japón, 062-0003
- Reclutamiento
- Hanaoka Seishu Memorial Hospital
-
-
Hyōgo
-
Kawanishi, Hyōgo, Japón, 666-0125
- Reclutamiento
- The Veritas Hospital
-
-
Ibaraki
-
Higashiibaraki District, Ibaraki, Japón, 311-3193
- Reclutamiento
- National Hospital Organization Mito Medical Center
-
Tsuchiura, Ibaraki, Japón, 300-8585
- Reclutamiento
- National Hospital Organization Kasumigaura Medical Center
-
-
Kanagawa
-
Yokohama, Kanagawa, Japón, 234-0054
- Reclutamiento
- Saiseikai Yokohama-shi Nanbu Hospital
-
-
Kyoto
-
Kyoto, Kyoto, Japón, 607-8062
- Reclutamiento
- Rakuwakai Otowa Hospital
-
-
Yokohama-shi
-
Kanagawa, Yokohama-shi, Japón, 247-0005
- Reclutamiento
- JA Tsuchiura Kyodo General Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Key Inclusion Criteria:
-
Has AF or flutter (paroxysmal or persistent), not considered to be secondary to a reversible cause, and an indication for indefinite anticoagulation treatment as described in the protocol
-
Meets one of the following:
- CHA2DS2-VA [C: Congestive heart failure; H: Hypertension; A2: Age ≥75 years (double points); D: Diabetes mellitus; S2: Stroke or TIA or Systemic embolism (double points); V: Vascular disease; A: Age 65-74 years] score ≥2 and Oral Anticoagulant (OAC) naïve OR
- CHA2DS2-VA score ≥3 OR
- CHA2DS2-VA score of 2 AND at least 1 enrichment criteria as described in the protocol
-
Must have an International Normalized Ratio (INR) <2.5 at the time of randomization if taking warfarin or another Vitamin K Antagonist (VKA)
Key Exclusion Criteria:
- Has a mechanical heart valve prosthesis (Note: transcatheter aortic valve replacement is not an exclusion)
- Has known moderate-to-severe mitral stenosis
- Has had a successful ablation therapy without documented recurrent AF or a participant after Left Atrial Appendage (LAA) occlusion/exclusion or plan for ablation or LAA occlusion/exclusion within the next 6 months starting from randomization
- Had an ischemic stroke within 2 days prior to randomization
- Has persistent, uncontrolled hypertension (per investigator's discretion)
- Has estimated Glomerular Filtration Rate (eGFR) <15 mL/min/1.73m2 within 30 days prior to randomization or is on dialysis or expected to be started on dialysis within the next 6 months starting from randomization
Note: Other protocol-defined Inclusion/ Exclusion criteria apply
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: REGN7508 + Placebo
|
Administered per the protocol Administered per the protocol
Otros nombres:
|
|
Comparador activo: Apixaban + Placebo
|
Administered per the protocol Administered per the protocol |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Time to first occurrence of stroke (ischemic, hemorrhagic, or of unspecified type) or systemic embolism
Periodo de tiempo: Approximately 36 months
|
Approximately 36 months
|
|
Time to first occurrence of International Society on Thrombosis and Haemostasis (ISTH) major bleeding or ISTH Clinically Relevant Non-Major (CRNM) bleeding
Periodo de tiempo: Approximately 36 months
|
Approximately 36 months
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Time to first occurrence of stroke (ischemic, hemorrhagic, or of unspecified type), systemic embolism, ISTH major bleeding, or ISTH CRNM bleeding
Periodo de tiempo: Approximately 36 months
|
Approximately 36 months
|
|
Time to first occurrence of stroke (ischemic, hemorrhagic, or of unspecified type), systemic embolism, or ISTH major bleeding
Periodo de tiempo: Approximately 36 months
|
Approximately 36 months
|
|
Time to first occurrence of stroke (ischemic, hemorrhagic, or of unspecified type), systemic embolism, ISTH major bleeding, or all-cause death
Periodo de tiempo: Approximately 36 months
|
Approximately 36 months
|
|
Time to first occurrence of ISTH major bleeding
Periodo de tiempo: Approximately 36 months
|
Approximately 36 months
|
|
Time to first occurrence of hemorrhagic stroke, intracerebral hemorrhage, or hemorrhagic transformation of an ischemic stroke
Periodo de tiempo: Approximately 36 months
|
Approximately 36 months
|
|
Time to occurrence of fatal bleeding
Periodo de tiempo: Approximately 36 months
|
Approximately 36 months
|
|
Number of ISTH major bleeding events
Periodo de tiempo: Approximately 36 months
|
Approximately 36 months
|
|
Number of ISTH CRNM bleeding events
Periodo de tiempo: Approximately 36 months
|
Approximately 36 months
|
|
Number of minor bleeding events
Periodo de tiempo: Approximately 36 months
|
Approximately 36 months
|
|
Time to all-cause death
Periodo de tiempo: Approximately 36 months
|
Approximately 36 months
|
|
Occurrence of Treatment-Emergent Adverse Events (TEAEs)
Periodo de tiempo: Approximately 39 months
|
Approximately 39 months
|
|
Severity of TEAEs
Periodo de tiempo: Approximately 39 months
|
Approximately 39 months
|
|
Occurrence of Anti-Drug Antibodies (ADA) to REGN7508
Periodo de tiempo: Approximately 36 months
|
Approximately 36 months
|
|
Magnitude of ADA to REGN7508
Periodo de tiempo: Approximately 36 months
|
Approximately 36 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Clinical Trial Management, Regeneron Pharmaceuticals
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Trastornos cerebrovasculares
- Enfermedades Cerebrales
- Enfermedades del Sistema Nervioso Central
- Enfermedades del Sistema Nervioso
- Enfermedades Vasculares
- Enfermedades cardiovasculares
- Procesos Patológicos
- Enfermedades cardíacas
- Arritmias Cardiacas
- Embolia y Trombosis
- Condiciones Patológicas, Signos y Síntomas
- Carrera
- Trombosis
- Fibrilación auricular
- Hemorragia
- apixaban
Otros números de identificación del estudio
- R7508-CVA-24114
- 2025-521617-97-00 (Ctis)
- 2025 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Marco de tiempo para compartir IPD
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
Criterios de acceso compartido de IPD
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
- CIF
- CÓDIGO_ANALÍTICO
- RSC
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .